Evidence map›Paper›PMID 42440568›Full record

ArticleClinical case reports2026

Advanced Management of Acute Intermittent Porphyria: The Role of Givosiran Therapy in Improving Long-Term Outcomes-A Case Study.

Natália Rebeca Alves de Araújo Karpejany, Jose Tiburcio do Monte Neto, Ester Miranda Pereira, Isabel Andrea Ferreira Carvalho, Rafael Melo Santos de Serpa Brandão, Adalberto Socorro da Silva, Tiberio Silva Borges Dos Santos, Semiramis Jamil Hadad do Monte

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Natália Rebeca Alves de Araújo KarpejanyHospital Universitário da Universidade Federal do Piauí Teresina Brazil.ORCID https://orcid.org/0000-0002-8450-8201
Jose Tiburcio do Monte NetoLaboratório de Imunogenética e Biologia Molecular - Universidade Federal do Piauí Teresina Brazil.ORCID https://orcid.org/0009-0001-6862-8297
Ester Miranda PereiraLaboratório de Imunogenética e Biologia Molecular - Universidade Federal do Piauí Teresina Brazil.ORCID https://orcid.org/0000-0001-6817-251X
Isabel Andrea Ferreira CarvalhoHospital Universitário da Universidade Federal do Piauí Teresina Brazil.ORCID https://orcid.org/0009-0005-3441-7175
Rafael Melo Santos de Serpa BrandãoLaboratório de Imunogenética e Biologia Molecular - Universidade Federal do Piauí Teresina Brazil.ORCID https://orcid.org/0000-0002-8718-7140
Adalberto Socorro da SilvaLaboratório de Imunogenética e Biologia Molecular - Universidade Federal do Piauí Teresina Brazil.ORCID https://orcid.org/0000-0002-9939-530X
Tiberio Silva Borges Dos SantosHospital Universitário da Universidade Federal do Piauí Teresina Brazil.ORCID https://orcid.org/0000-0002-0767-0934
Semiramis Jamil Hadad do MonteLaboratório de Imunogenética e Biologia Molecular - Universidade Federal do Piauí Teresina Brazil.ORCID https://orcid.org/0000-0001-9455-2161

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute intermittent porphyria is a rare disorder causing neurotoxic precursor accumulation and severe neurological complications. We report a case progressing to tetraplegia and respiratory failure with delayed diagnosis. Treatment with hemin and givosiran resulted in prevention of attacks and functional recovery, highlighting the importance of early diagnosis and long-term therapy.

Indexed as

acute intermittent porphyriagene silencinggivosiranheminhydroxymethylbilane synthase

Identifiers

PMID42440568
PMCPMC13333651

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.